Citations (127)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Thomas Müller. (2023) The role of istradefylline in the Parkinson’s disease armamentarium. Expert Opinion on Pharmacotherapy 24:7, pages 863-871.
Read now
Read now
Nabil Al-Zaqri, T. Pooventhiran, Ali Alsalme, D. Jagadeeswara Rao, Siriki Srinivasa Rao, A. Sankar & Renjith Thomas. (2022) First-Principle Studies of Istradefylline with Emphasis on the Stability, Reactivity, Interactions and Wavefunction-Dependent Properties. Polycyclic Aromatic Compounds 42:6, pages 3238-3252.
Read now
Read now
Peter Jenner, Akihisa Mori, Stephen D. Aradi & Robert A. Hauser. (2021) Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease. Expert Review of Neurotherapeutics 21:3, pages 317-333.
Read now
Read now
Margherita Torti, Laura Vacca & Fabrizio Stocchi. (2018) Istradefylline for the treatment of Parkinson’s disease: is it a promising strategy?. Expert Opinion on Pharmacotherapy 19:16, pages 1821-1828.
Read now
Read now
Ruxandra Julia Vorovenci & Angelo Antonini. (2015) The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease. Expert Review of Neurotherapeutics 15:12, pages 1383-1390.
Read now
Read now
Chuan Zhu, Guowei Wang, Jinqing Li, Li Chen, Chaoli Wang, Yajie Wang, Ping Lin & Hong Ran. (2014) Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson’s disease: a meta-analysis. Neurological Research 36:11, pages 1028-1034.
Read now
Read now
Murty Deverakonda, Raghu
Prasad Mailavaram, Pran
Kishore Deb, Narsaiah Banda & Girija
Sastry Vedula. (2012) Rapid and Efficient, Microwave-Assisted, Base-Catalyzed Synthesis of Some Novel 2,7-Disubstituted Pyrrolopyrimidinones. Synthetic Communications 42:21, pages 3103-3111.
Read now
Read now
Annalisa Pinna. (2009) Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. Expert Opinion on Investigational Drugs 18:11, pages 1619-1631.
Read now
Read now
Roberto Scatena, Giuseppe E Martorana, Patrizia Bottoni, Giorgia Botta, Paola Pastore & Bruno Giardina. (2007) An update on pharmacological approaches to neurodegenerative diseases. Expert Opinion on Investigational Drugs 16:1, pages 59-72.
Read now
Read now
Aloke K Dutta PhD & Weidong Le MD, PhD. (2006) Existing dopaminergic therapies for Parkinson’s disease. Expert Opinion on Therapeutic Patents 16:12, pages 1613-1625.
Read now
Read now
Thomas Müller & Hermann Russ. (2006) Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease. Expert Opinion on Pharmacotherapy 7:13, pages 1715-1730.
Read now
Read now
Articles from other publishers (116)
Barbara Kutryb-Zając, Ada Kawecka, Khrystyna Nasadiuk, Alicja Braczko, Klaudia Stawarska, Elisabetta Caiazzo, Patrycja Koszałka & Carla Cicala. (2023) Drugs targeting adenosine signaling pathways: A current view. Biomedicine & Pharmacotherapy 165, pages 115184.
Crossref
Crossref
Mohammad Ahmed Khan, Nafis Haider, Tanveer Singh, Ritam Bandopadhyay, Mohammed M. Ghoneim, Sultan Alshehri, Murtada Taha, Javed Ahmad & Awanish Mishra. (2023) Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research. Metabolic Brain Disease 38:3, pages 873-919.
Crossref
Crossref
Nelson Tibashailwa, Flora Stephano, Daniel M. Shadrack, Joan J.E. Munissi & Stephen S. Nyandoro. (2023) Neuroprotective potential of cinnamoyl derivatives against Parkinson’s disease indicators in Drosophila melanogaster and in silico models. NeuroToxicology 94, pages 147-157.
Crossref
Crossref
Raphaël Bolteau, Romain Duroux, Amélie Laversin, Brandon Vreulz, Anna Shiriaeva, Benjamin Stauch, Gye Won Han, Vadim Cherezov, Nicolas Renault, Amélie Barczyk, Séverine Ravez, Mathilde Coevoet, Patricia Melnyk, Maxime Liberelle & Saïd Yous. (2022) High ligand efficiency quinazoline compounds as novel A2A adenosine receptor antagonists. European Journal of Medicinal Chemistry 241, pages 114620.
Crossref
Crossref
Christopher J. Earley, Byron C. Jones & Sergi Ferré. (2022) Brain-iron deficiency models of restless legs syndrome. Experimental Neurology 356, pages 114158.
Crossref
Crossref
Javed Ahmad, Nafis Haider, Mohammad Ahmed Khan, Shadab Md, Nabil A. Alhakamy, Mohammed M. Ghoneim, Sultan Alshehri, Syed Sarim Imam, Mohammad Zaki Ahmad & Awanish Mishra. (2022) Novel therapeutic interventions for combating Parkinson’s disease and prospects of Nose-to-Brain drug delivery. Biochemical Pharmacology 195, pages 114849.
Crossref
Crossref
Palanisamy Sivanandy, Tan Choo Leey, Tan Chi Xiang, Tan Chi Ling, Sean Ang Wey Han, Samantha Lia Anak Semilan & Phoon Kok Hong. (2021) Systematic Review on Parkinson’s Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson’s Symptoms. International Journal of Environmental Research and Public Health 19:1, pages 364.
Crossref
Crossref
Min Shin, Madhavi Pandya, Kristan Espinosa, Ravindra Telang, Jordi Boix, Peter R. Thorne & Srdjan M. Vlajkovic. (2021) Istradefylline Mitigates Age-Related Hearing Loss in C57BL/6J Mice. International Journal of Molecular Sciences 22:15, pages 8000.
Crossref
Crossref
Amnon A. Berger, Ariel Winnick, Alexandra Welschmeyer, Alicia Kaneb, Kevin Berardino, Elyse M. Cornett, Alan D. Kaye, Omar Viswanath & Ivan Urits. (2020) Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review. Neurology International 12:3, pages 109-129.
Crossref
Crossref
Fernanda Rodríguez-Enríquez, María Carmen Costas-Lago, Pedro Besada, Miguel Alonso-Pena, Iria Torres-Terán, Dolores Viña, José Ángel Fontenla, Mattia Sturlese, Stefano Moro, Elias Quezada & Carmen Terán. (2020) Novel coumarin-pyridazine hybrids as selective MAO-B inhibitors for the Parkinson’s disease therapy. Bioorganic Chemistry 104, pages 104203.
Crossref
Crossref
Yuri Park, Min-Ho Park, Jin-Ju Byeon, Seok-Ho Shin, Byeong ill Lee, Jang-mi Choi, Nahye Kim, Seo-jin Park, Min-jae Park, Jeong-hyeon Lim & Young G. Shin. (2020) Assessment of Pharmacokinetics and Metabolism Profiles of SCH 58261 in Rats Using Liquid Chromatography–Mass Spectrometric Method. Molecules 25:9, pages 2209.
Crossref
Crossref
Sergi FerréFrancisco Ciruela. (2019)
Functional and Neuroprotective Role of Striatal Adenosine A
2A
Receptor Heterotetramers
. Journal of Caffeine and Adenosine Research 9:3, pages 89-97.
Crossref
Crossref
Widya Dwi Aryati, Nabilah Nurtika Salamah, Rezi Riadhi Syahdi & Arry Yanuar. 2019. Neuroprotection. Neuroprotection.
Belinda RX Han, Shelly CY Lin, Kristan Espinosa, Peter R Thorne & Srdjan M Vlajkovic. (2019) Inhibition of the Adenosine A2A Receptor Mitigates Excitotoxic Injury in Organotypic Tissue Cultures of the Rat Cochlea. Cells 8:8, pages 877.
Crossref
Crossref
Jiyue Zheng, Xiaohu Zhang & Xuechu Zhen. (2018)
Development of Adenosine A
2A
Receptor Antagonists for the Treatment of Parkinson’s Disease: A Recent Update and Challenge
. ACS Chemical Neuroscience 10:2, pages 783-791.
Crossref
Crossref
Xinjian Zhang, Taku Nagai, Rijwan Uddin Ahammad, Keisuke Kuroda, Shinichi Nakamuta, Takashi Nakano, Naoto Yukinawa, Yasuhiro Funahashi, Yukie Yamahashi, Mutsuki Amano, Junichiro Yoshimoto, Kiyofumi Yamada & Kozo Kaibuchi. (2019) Balance between dopamine and adenosine signals regulates the PKA/Rap1 pathway in striatal medium spiny neurons. Neurochemistry International 122, pages 8-18.
Crossref
Crossref
Fabiana Núñez, Jaume Taura, Juan Camacho, Marc López-Cano, Víctor Fernández-Dueñas, Naomi Castro, Julio Castro & Francisco Ciruela. (2018) PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders. Frontiers in Pharmacology 9.
Crossref
Crossref
Shaherin Basith, Minghua Cui, Stephani J. Y. Macalino, Jongmi Park, Nina A. B. Clavio, Soosung Kang & Sun Choi. (2018) Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design. Frontiers in Pharmacology 9.
Crossref
Crossref
John D. Salamone & Mercè Correa. 2018.
129
167
.
Caio M. Massari, Marc López-Cano, Fabiana Núñez, Víctor Fernández-Dueñas, Carla I. Tasca & Francisco Ciruela. (2017) Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder. Frontiers in Pharmacology 8.
Crossref
Crossref
Xavier Morató, Rafael Luján, Marc López-Cano, Jorge Gandía, Igor Stagljar, Masahiko Watanabe, Rodrigo A. Cunha, Víctor Fernández-Dueñas & Francisco Ciruela. (2017) The Parkinson’s disease-associated GPR37 receptor interacts with striatal adenosine A2A receptor controlling its cell surface expression and function in vivo. Scientific Reports 7:1.
Crossref
Crossref
Melanie Mediavilla-Varela, Julio Castro, Alberto Chiappori, David Noyes, Dalia C. Hernandez, Bertrand Allard, John Stagg & Scott J. Antonia. (2017) A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. Neoplasia 19:7, pages 530-536.
Crossref
Crossref
Paulo A. de Oliveira, James A. R. Dalton, Marc López-Cano, Adrià Ricarte, Xavier Morató, Filipe C. Matheus, Andréia S. Cunha, Christa E. Müller, Reinaldo N. Takahashi, Víctor Fernández-Dueñas, Jesús Giraldo, Rui D. Prediger & Francisco Ciruela. (2017) Angiotensin II type 1/adenosine A
2A
receptor oligomers: a novel target for tardive dyskinesia. Scientific Reports 7:1.
Crossref
Crossref
Zhaohui Yang, Linlang Li, Jiyue Zheng, Haikuo Ma, Sheng Tian, Jiajun Li, Hongjian Zhang, Xuechu Zhen & Xiaohu Zhang. (2016)
Identification of a New Series of Potent Adenosine A
2A
Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson’s Disease
. ACS Chemical Neuroscience 7:11, pages 1575-1584.
Crossref
Crossref
S. Butini, K. Nikolic, S. Kassel, H. Brückmann, S. Filipic, D. Agbaba, S. Gemma, S. Brogi, M. Brindisi, G. Campiani & H. Stark. (2016) Polypharmacology of dopamine receptor ligands. Progress in Neurobiology 142, pages 68-103.
Crossref
Crossref
Amira M. Soliman, Ahmed M. Fathalla & Ahmed A. Moustafa. (2016) Dose-dependent neuroprotective effect of caffeine on a rotenone-induced rat model of parkinsonism: A histological study. Neuroscience Letters 623, pages 63-70.
Crossref
Crossref
Gang Zhou, Robert Aslanian, Gioconda Gallo, Tanweer Khan, Rongze Kuang, Biju Purakkattle, Manuel De Ruiz, Andrew Stamford, Pauline Ting, Heping Wu, Hongwu Wang, Dong Xiao, Tao Yu, Yonglian Zhang, Deborra Mullins & Robert Hodgson. (2016) Discovery of aminoquinazoline derivatives as human A2A adenosine receptor antagonists. Bioorganic & Medicinal Chemistry Letters 26:4, pages 1348-1354.
Crossref
Crossref
Mohamad Wessam Alnouri, Stephan Jepards, Alessandro Casari, Anke C. Schiedel, Sonja Hinz & Christa E. Müller. (2015) Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors. Purinergic Signalling 11:3, pages 389-407.
Crossref
Crossref
Tomoyoshi Kondo & Yoshikuni Mizuno. (2015) A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease. Clinical Neuropharmacology 38:2, pages 41-46.
Crossref
Crossref
Gitte Kobber?e Mikkelsen, Morten Langg?rd, Tenna Juul Schr?der, Mads Kreilgaard, Erling B. J?rgensen, Guillaume Brandt, Yann Griffon, Ray Boffey & Benny Bang-Andersen. (2015) Synthesis and SAR studies of analogues of 4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-N-thiazol-2-yl-benzamide (Lu AA41063) as adenosine A2A receptor ligands with improved aqueous solubility. Bioorganic & Medicinal Chemistry Letters 25:6, pages 1212-1216.
Crossref
Crossref
Jiyue Zheng, Zhaohui Yang, Xuan Li, Linlang Li, Haikuo Ma, Meiyu Wang, Hongjian Zhang, Xuechu Zhen & Xiaohu Zhang. (2014)
Optimization of 6-Heterocyclic-2-(1
H
-pyrazol-1-yl)-
N
-(pyridin-2-yl)pyrimidin-4-amine as Potent Adenosine A
2A
Receptor Antagonists for the Treatment of Parkinson’s Disease
. ACS Chemical Neuroscience 5:8, pages 674-682.
Crossref
Crossref
Marc Brugarolas, Gemma Navarro, Eva Martínez-Pinilla, Edgar Angelats, Vicent Casadó, José L. Lanciego & Rafael Franco. (2014) G-Protein-Coupled Receptor Heteromers as Key Players in the Molecular Architecture of the Central Nervous System. CNS Neuroscience & Therapeutics 20:8, pages 703-709.
Crossref
Crossref
Annalisa Pinna. (2014) Adenosine A2A Receptor Antagonists in Parkinson?s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued. CNS Drugs 28:5, pages 455-474.
Crossref
Crossref
Annalisa Pinna, Jordi Bonaventura, Daniel Farr?Marta S?nchez, Nicola Simola, Josefa Mallol, Carme Llu?s, Giulia Costa, Younis Baqi, Christa E. M?ller, Antoni Cort?s, Peter McCormick, Enric I. Canela, Eva Mart?nez-Pinilla, Jos? L. Lanciego, Vicent Casad?Marie-Therese Armentero & Rafael Franco. (2014) l-DOPA disrupts adenosine A2A?cannabinoid CB1?dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies. Experimental Neurology 253, pages 180-191.
Crossref
Crossref
Stephen P. Andrews, Giles A. Brown & John A. Christopher. (2014) Structure-Based and Fragment-Based GPCR Drug Discovery. ChemMedChem 9:2, pages 256-275.
Crossref
Crossref
Zhaohui Yang, Xuan Li, Haikuo Ma, Jiyue Zheng, Xuechu Zhen & Xiaohu Zhang. (2014) Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists. Bioorganic & Medicinal Chemistry Letters 24:1, pages 152-155.
Crossref
Crossref
Joanne Bronson, Amelia Black, Murali Dhar, Bruce Ellsworth & J. Robert Merritt. 2014.
437
508
.
Takako Kadowaki Horita, Minoru Kobayashi, Akihisa Mori, Peter Jenner & Tomoyuki Kanda. (2013) Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology 230:3, pages 345-352.
Crossref
Crossref
Eric J. Nunes, Patrick A. Randall, Samantha Podurgiel, Merc? Correa & John D. Salamone. (2013) Nucleus accumbens neurotransmission and effort-related choice behavior in food motivation: Effects of drugs acting on dopamine, adenosine, and muscarinic acetylcholine receptors. Neuroscience & Biobehavioral Reviews 37:9, pages 2015-2025.
Crossref
Crossref
Mayumi Saki, Koji Yamada, Etsuko Koshimura, Katsutoshi Sasaki & Tomoyuki Kanda. (2013) In vitro pharmacological profile of the A2A receptor antagonist istradefylline. Naunyn-Schmiedeberg's Archives of Pharmacology 386:11, pages 963-972.
Crossref
Crossref
S.J. Podurgiel, E.J. Nunes, S.E. Yohn, J. Barber, A. Thompson, M. Milligan, C.A. Lee, L. López-Cruz, M. Pardo, O. Valverde, C. Lendent, Y. Baqi, C.E. Müller, M. Correa & J.D. Salamone. (2013) The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: Implications for pharmacological models of parkinsonian tremor. Neuroscience 250, pages 507-519.
Crossref
Crossref
Lyndsey E. Collins-Praino, Nicholas E. Paul, Felicia Ledgard, Samantha J. Podurgiel, Rotem Kovner, Younis Baqi, Christa E. Müller, Patrick B. Senatus & John D. Salamone. (2013)
Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A
2A
antagonism
. European Journal of Neuroscience 38:1, pages 2183-2191.
Crossref
Crossref
Yoshikuni Mizuno & Tomoyoshi Kondo. (2013)
Adenosine A
2A
receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
. Movement Disorders 28:8, pages 1138-1141.
Crossref
Crossref
Rosselle Dungo & Emma D. Deeks. (2013) Istradefylline: First Global Approval. Drugs 73:8, pages 875-882.
Crossref
Crossref
Ilhuicamina Daniel Limón-Pérez de León, María del Carmen Parra-Cid, Alejandro Muñoz-Zurita, Saúl Alejandro Merino-Contreras, Sara Montiel-Smith, Socorro Meza-Reyes, Gerardo Ramírez-Mejía & Jesús Sandoval-Ramírez. (2013) Motor Effects of 1,3-Disubstituted 8-Styrylxanthines as A<sub>1</sub> and A<sub>2</sub> Adenosine-Receptor Antagonists in Rats. Pharmacology & Pharmacy 04:03, pages 303-311.
Crossref
Crossref
Sarah Lynch & Subbiah P. Sivam. (2013) Dopamine and GABA Interaction in Basal Ganglia: GABA-A or GABA-B Receptor Stimulation Attenuates L-DOPA-Induced Striatal and Nigral ERK1/2 Signaling in a Rat Model of Parkinson’s Disease. Journal of Behavioral and Brain Science 03:06, pages 479-488.
Crossref
Crossref
Sarah Lynch & Subbiah P. Sivam. (2013) GABA Attenuates L-DOPA-Induced Striatal and Nigral ERK1/2 Signaling in a Rat Model of Parkinson’s Disease. Journal of Behavioral and Brain Science 03:03, pages 320-330.
Crossref
Crossref
Stephen P. Andrews & Benjamin Tehan. (2013)
Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A
2A
receptor
. MedChemComm 4:1, pages 52-67.
Crossref
Crossref
Wanqiang Chen, Hongquan Wang, Hongtao Wei, Shuli Gu & Haiping Wei. (2013) Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: A meta-analysis. Journal of the Neurological Sciences 324:1-2, pages 21-28.
Crossref
Crossref
José L. Moreno, Terrell Holloway & Javier González-Maeso. 2013. Oligomerization in Health and Disease. Oligomerization in Health and Disease
187
205
.
John D. Salamone, Merce Correa, Patrick A. Randall, Eric J. Nunes, Marta Pardo & Laura Lopez-Cruz. 2013. Adenosine. Adenosine
493
512
.
Annalisa Pinna, Nicola Simola, Lucia Frau & Micaela Morelli. 2013. Adenosine. Adenosine
361
384
.
Naoko Kuzumaki, Atsuo Suzuki, Michiko Narita, Takahiro Hosoya, Atsumi Nagasawa, Satoshi Imai, Kohei Yamamizu, Hiroshi Morita, Tsutomu Suzuki, Yohei Okada, Hirotaka James Okano, Jun K. Yamashita, Hideyuki Okano & Minoru Narita. (2012) Multiple Analyses of G-Protein Coupled Receptor (GPCR) Expression in the Development of Gefitinib-Resistance in Transforming Non-Small-Cell Lung Cancer. PLoS ONE 7:10, pages e44368.
Crossref
Crossref
Ronald B. PostumaAnthony E. LangRenato P. MunhozKatia CharlandAmelie PelletierMariana MoscovichLuciane FillaDebora ZanattaSilvia Rios RomenetsRobert AltmanRosa ChuangBinit Shah. (2012) Caffeine for treatment of Parkinson disease. Neurology 79:7, pages 651-658.
Crossref
Crossref
Yousheng Xiao, Jin Wang, Shan Jiang & Hongye Luo. (2012) Hyperbaric oxygen therapy for vascular dementia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Yousheng Xiao, Lu Gan & Jin Wang. (2012)
Adenosine A
2A
receptor antagonist istradefylline for levodopa-induced complications in Parkinson's disease
. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Emmanuelle Pourcher, Hubert H. Fernandez, Mark Stacy, Akihisa Mori, Rocco Ballerini & Philip Chaikin. (2012) Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study. Parkinsonism & Related Disorders 18:2, pages 178-184.
Crossref
Crossref
Lyndsey E. Collins, Thomas N. Sager, Anette G. Sams, Adam Pennarola, Russell G. Port, Mona Shahriari & John D. Salamone. (2012) The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade. Pharmacology Biochemistry and Behavior 100:3, pages 498-505.
Crossref
Crossref
Marie Therese Armentero, Annalisa Pinna, Sergi Ferr?Jos? Luis Lanciego, Christa E. M?ller & Rafael Franco. (2011) Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacology & Therapeutics 132:3, pages 280-299.
Crossref
Crossref
Andrew?S. Dor?Nathan Robertson, James?C. Errey, Irene Ng, Kaspar Hollenstein, Ben Tehan, Edward Hurrell, Kirstie Bennett, Miles Congreve, Francesca Magnani, Christopher?G. Tate, Malcolm Weir & Fiona?H. Marshall. (2011) Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine. Structure 19:9, pages 1283-1293.
Crossref
Crossref
Andrei ZhukovStephen P. AndrewsJames C. ErreyNathan RobertsonBenjamin TehanJonathan S. MasonFiona H. MarshallMalcolm WeirMiles Congreve. (2011)
Biophysical Mapping of the Adenosine A
2A
Receptor
. Journal of Medicinal Chemistry 54:13, pages 4312-4323.
Crossref
Crossref
A.F. RamlackhansinghS.K. BoseI. AhmedF.E. TurkheimerN. PaveseD.J. Brooks. (2011) Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 76:21, pages 1811-1816.
Crossref
Crossref
Francisco Ciruela, Maricel G?mez-Soler, Diego Guidolin, Dasiel O. Borroto-Escuela, Luigi F. Agnati, Kjell Fuxe & V?ctor Fern?ndez-Due?as. (2011) Adenosine receptor containing oligomers: Their role in the control of dopamine and glutamate neurotransmission in the brain. Biochimica et Biophysica Acta (BBA) - Biomembranes 1808:5, pages 1245-1255.
Crossref
Crossref
Siew Lee Cheong, Gopalakrishnan Venkatesan, Priyankar Paira, Ramasamy Jothibasu, Alexander Laurence Mandel, Stephanie Federico, Giampiero Spalluto & Giorgia Pastorin. (2011) Pyrazolo Derivatives as Potent Adenosine Receptor Antagonists: An Overview on the Structure-Activity Relationships. International Journal of Medicinal Chemistry 2011, pages 1-15.
Crossref
Crossref
Joel M. Harris, Bernard R. Neustadt, Hongtao Zhang, Jean Lachowicz, Mary Cohen-Williams, Geoff Varty, Jinsong Hao & Andrew W. Stamford. (2011) Potent and selective adenosine A2A receptor antagonists: [1,2,4]-triazolo[4,3-c]pyrimidin-3-ones. Bioorganic & Medicinal Chemistry Letters 21:8, pages 2497-2501.
Crossref
Crossref
Anette G. Sams, Gitte K. Mikkelsen, Mogens Larsen, Morten Langgård, Mark E. Howells, Tenna J. Schrøder, Lise T. Brennum, Lars Torup, Erling B. Jørgensen, Christoffer Bundgaard, Mads Kreilgård & Benny Bang-Andersen. (2011)
Discovery of Phosphoric Acid Mono-{2-[(
E
/
Z
)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} Ester (Lu AA47070): A Phosphonooxymethylene Prodrug of a Potent and Selective hA
2A
Receptor Antagonist
. Journal of Medicinal Chemistry 54:3, pages 751-764.
Crossref
Crossref
Anna Drabczyńska, Małgorzata Zygmunt, Jacek Sapa, Barbara Filipek, Christa E. Müller & Katarzyna Kieć‐Kononowicz. (2010)
Antiparkinsonian Effects of Novel Adenosine A
2A
Receptor Antagonists
. Archiv der Pharmazie 344:1, pages 20-27.
Crossref
Crossref
Brian F. McGuinness, Andrew G. Cole, Guizhen Dong, Marc-Raleigh Brescia, Yuefei Shao, Ian Henderson, Laura L. Rokosz, Tara M. Stauffer, Neelima Mannava, Earl F. Kimble, Catherine Hicks, Nicole White, Pamela G. Wines & Elizabeth Quadros. (2010) Discovery of 2-aminoimidazopyridine adenosine A2A receptor antagonists. Bioorganic & Medicinal Chemistry Letters 20:22, pages 6845-6849.
Crossref
Crossref
E.J. Nunes, P.A. Randall, J.L. Santerre, A.B. Given, T.N. Sager, M. Correa & J.D. Salamone. (2010) Differential effects of selective adenosine antagonists on the effort-related impairments induced by dopamine D1 and D2 antagonism. Neuroscience 170:1, pages 268-280.
Crossref
Crossref
Anette Graven Sams, Gitte Kobber?e Mikkelsen, Mogens Larsen, Lars Torup, Lise T?ttrup Brennum, Tenna Juul Schr?der & Benny Bang-Andersen. (2010) Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists. Bioorganic & Medicinal Chemistry Letters 20:17, pages 5241-5244.
Crossref
Crossref
Yoshikuni Mizuno, Kazuko Hasegawa, Tomoyoshi Kondo, Sadako Kuno & Mitsutoshi Yamamoto. (2010) Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: A randomized, controlled study. Movement Disorders 25:10, pages 1437-1443.
Crossref
Crossref
K. Fuxe, D. Marcellino, D. O. Borroto‐Escuela, M. Guescini, V. Fernández‐Dueñas, S. Tanganelli, A. Rivera, F. Ciruela & L. F. Agnati. (2010) Adenosine–Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders. CNS Neuroscience & Therapeutics 16:3.
Crossref
Crossref
John D Salamone, Merce Correa, Andrew M Farrar, Eric J Nunes. (2010) Role of dopamine–adenosine interactions in the brain circuitry regulating effort-related decision making: insights into pathological aspects of motivation. Future Neurology 5:3, pages 377-392.
Crossref
Crossref
Annalisa Pinna, Elisabetta Tronci, Nicoletta Schintu, Nicola Simola, Rosaria Volpini, Silvia Pontis, Gloria Cristalli & Micaela Morelli. (2010) A new ethyladenine antagonist of adenosine A2A receptors: Behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology 58:3, pages 613-623.
Crossref
Crossref
Katia Varani, Fabrizio Vincenzi, Alice Tosi, Stefania Gessi, Ilaria Casetta, Gino Granieri, Patrik Fazio, Edward Leung, Stephen MacLennan, Enrico Granieri & Pier Andrea Borea. (2009)
A
2A
adenosine receptor overexpression and functionality, as well as TNF‐α levels, correlate with motor symptoms in Parkinson's disease
. The FASEB Journal 24:2, pages 587-598.
Crossref
Crossref
Lyndsey E. Collins, Daniel J. Galtieri, Lise T. Brennum, Thomas N. Sager, Jörg Hockemeyer, Christa E. Müller, James R. Hinman, James J. Chrobak & John D. Salamone. (2010) Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX. Pharmacology Biochemistry and Behavior 94:4, pages 561-569.
Crossref
Crossref
H.H. Fernandez, D.R. Greeley, R.M. Zweig, J. Wojcieszek, A. Mori & N.M. Sussman. (2010) Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial. Parkinsonism & Related Disorders 16:1, pages 16-20.
Crossref
Crossref
Sai-jun Zhou, Mei-er Zhu, Dan Shu, Xun-ping Du, Xiu-hua Song, Xiao-tong Wang, Rong-yuan Zheng, Xiao-hong Cai, Jiang-fan Chen & Jin-cai He. (2009) Preferential enhancement of working memory in mice lacking adenosine A2A receptors. Brain Research 1303, pages 74-83.
Crossref
Crossref
A.J. Betz, R. Vontell, J. Valenta, L. Worden, K.S. Sink, L. Font, M. Correa, T.N. Sager & J.D. Salamone. (2009) Effects of the adenosine A2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide. Neuroscience 163:1, pages 97-108.
Crossref
Crossref
John D. Salamone, Andrew M. Farrar, Laura Font, Vatsal Patel, Devra E. Schlar, Eric J. Nunes, Lyndsey E. Collins & Thomas N. Sager. (2009) Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism. Behavioural Brain Research 201:1, pages 216-222.
Crossref
Crossref
Jennifer Trevitt, Christopher Vallance, Allison Harris & Tamara Goode. (2009) Adenosine antagonists reverse the cataleptic effects of haloperidol: Implications for the treatment of Parkinson's disease. Pharmacology Biochemistry and Behavior 92:3, pages 521-527.
Crossref
Crossref
Lila T. Worden, Mona Shahriari, Andrew M. Farrar, Kelly S. Sink, Jörg Hockemeyer, Christa E. Müller & John D. Salamone. (2008) The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists. Psychopharmacology 203:3, pages 489-499.
Crossref
Crossref
Marion C. Lanier, Manisha Moorjani, Zhiyong Luo, Yongsheng Chen, Emily Lin, John E. Tellew, Xiaohu Zhang, John P. Williams, Raymond S. Gross, Sandra M. Lechner, Stacy Markison, Tanya Joswig, William Kargo, Jaime Piercey, Mark Santos, Siobhan Malany, Marilyn Zhao, Robert Petroski, María I. Crespo, José-Luis Díaz, John Saunders, Jenny Wen, Zhihong O’Brien, Kayvon Jalali, Ajay Madan & Deborah H. Slee. (2009)
N
-[6-Amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A
2A
Receptor Antagonists with Improved Drug Like Properties and in Vivo Efficacy
. Journal of Medicinal Chemistry 52:3, pages 709-717.
Crossref
Crossref
Seema Gulyani, Christopher J. Earley, Simonetta Camandola, Stuart Maudsley, Sergi Ferré, Mohamed R. Mughal, Bronwen Martin, Aiwu Cheng, Marc Gleichmann, Byron C. Jones, Richard P. Allen & Mark P. Mattson. (2009) Diminished iron concentrations increase adenosine A2A receptor levels in mouse striatum and cultured human neuroblastoma cells. Experimental Neurology 215:2, pages 236-242.
Crossref
Crossref
Andrew G. Cole, Tara M. Stauffer, Laura L. Rokosz, Axel Metzger, Lawrence W. Dillard, Wenguang Zeng & Ian Henderson. (2009) Synthesis of 2-amino-5-benzoyl-4-(2-furyl)thiazoles as adenosine A2A receptor antagonists. Bioorganic & Medicinal Chemistry Letters 19:2, pages 378-381.
Crossref
Crossref
P. Fishman, S. Bar-Yehuda, M. Synowitz, J.D. Powell, K.N. Klotz, S. Gessi & P.A. Borea. 2009. Adenosine Receptors in Health and Disease. Adenosine Receptors in Health and Disease
399
441
.
Marek Cieślak, Michał Komoszyński & Andrzej Wojtczak. (2008) Adenosine A2A receptors in Parkinson’s disease treatment. Purinergic Signalling 4:4.
Crossref
Crossref
Geoffrey B. Varty, Robert A. Hodgson, Annamarie J. Pond, Michael E. Grzelak, Eric M. Parker & John C. Hunter. (2008) The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates. Psychopharmacology 200:3, pages 393-401.
Crossref
Crossref
Laura Font, Susana Mingote, Andrew M. Farrar, Mariana Pereira, Lila Worden, Colin Stopper, Russell G. Port & John D. Salamone. (2008) Intra-accumbens injections of the adenosine A2A agonist CGS 21680 affect effort-related choice behavior in rats. Psychopharmacology 199:4, pages 515-526.
Crossref
Crossref
Rafael Franco, Vicent Casadó, Antonio Cortés, Kamil Pérez-Capote, Josefa Mallol, Enric Canela, Sergi Ferré & Carme Lluis. (2008) Novel pharmacological targets based on receptor heteromers. Brain Research Reviews 58:2, pages 475-482.
Crossref
Crossref
K. Fuxe, D. Marcellino, A. Rivera, Z. Diaz-Cabiale, M. Filip, B. Gago, D.C.S. Roberts, U. Langel, S. Genedani, L. Ferraro, A. de la Calle, J. Narvaez, S. Tanganelli, A. Woods & L.F. Agnati. (2008) Receptor?receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Research Reviews 58:2, pages 415-452.
Crossref
Crossref
John D. Salamone, Keita Ishiwari, Adrienne J. Betz, Andrew M. Farrar, Susana M. Mingote, Laura Font, Jörg Hockemeyer, Christa E. Müller & Mercè Correa. (2008) Dopamine/adenosine interactions related to locomotion and tremor in animal models: Possible relevance to parkinsonism. Parkinsonism & Related Disorders 14, pages S130-S134.
Crossref
Crossref
M. StacyD. SilverT. MendisJ. SuttonA. MoriP. ChaikinN. M. Sussman. (2008) A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 70:23, pages 2233-2240.
Crossref
Crossref
Susana Mingote, Mariana Pereira, Andrew M. Farrar, Peter J. McLaughlin & John D. Salamone. (2008) Systemic administration of the adenosine A2A agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intake. Pharmacology Biochemistry and Behavior 89:3, pages 345-351.
Crossref
Crossref
Tomomi Shindou, Gordon W. Arbuthnott & Jeffery R. Wickens. (2008)
Actions of Adenosine A
2A
Receptors on Synaptic Connections of Spiny Projection Neurons in the Neostriatal Inhibitory Network
. Journal of Neurophysiology 99:4, pages 1884-1889.
Crossref
Crossref
Deborah H. Slee, Manisha Moorjani, Xiaohu Zhang, Emily Lin, Marion C. Lanier, Yongsheng Chen, Jaimie K. Rueter, Sandra M. Lechner, Stacy Markison, Siobhan Malany, Tanya Joswig, Mark Santos, Raymond S. Gross, John P. Williams, Julio C. Castro-Palomino, María I. Crespo, Maria Prat, Silvia Gual, José-Luis Díaz, Kayvon Jalali, Yang Sai, Zhiyang Zuo, Chun Yang, Jenny Wen, Zhihong O’Brien, Robert Petroski & John Saunders. (2008)
2-Amino-
N
-pyrimidin-4-ylacetamides as A
2A
Receptor Antagonists: 2. Reduction of hERG Activity, Observed Species Selectivity, and Structure−Activity Relationships
. Journal of Medicinal Chemistry 51:6, pages 1730-1739.
Crossref
Crossref
Xiaohu Zhang, Jaimie K. Rueter, Yongsheng Chen, Manisha Moorjani, Marion C. Lanier, Emily Lin, Raymond S. Gross, John E. Tellew, John P. Williams, Sandra M. Lechner, Stacy Markison, Tanya Joswig, Siobhan Malany, Mark Santos, Julio C. Castro-Palomino, Marı´a I. Crespo, Maria Prat, Silvia Gual, José-Luis Díaz, John Saunders & Deborah H. Slee. (2008) Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists. Bioorganic & Medicinal Chemistry Letters 18:6, pages 1778-1783.
Crossref
Crossref
Joseph Jankovic. (2008) Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?. Annals of Neurology 63:3, pages 267-269.
Crossref
Crossref
Peter A. LeWitt, M. Guttman, James W. Tetrud, Paul J. Tuite, Akihisa Mori, Philip Chaikin & Neil M. Sussman. (2008)
Adenosine A
2A
receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)
. Annals of Neurology 63:3, pages 295-302.
Crossref
Crossref
Deborah H. Slee, Xiaohu Zhang, Manisha Moorjani, Emily Lin, Marion C. Lanier, Yongsheng Chen, Jaimie K. Rueter, Sandra M. Lechner, Stacy Markison, Siobhan Malany, Tanya Joswig, Mark Santos, Raymond S. Gross, John P. Williams, Julio C. Castro-Palomino, María I. Crespo, Maria Prat, Silvia Gual, José-Luis Díaz, Jenny Wen, Zhihong O’Brien & John Saunders. (2008)
Identification of Novel, Water-Soluble, 2-Amino-
N
-pyrimidin-4-yl Acetamides as A
2A
Receptor Antagonists with In Vivo Efficacy
. Journal of Medicinal Chemistry 51:3, pages 400-406.
Crossref
Crossref
Tomoyuki Kanda & Akihisa Mori. (2008) Recent and potential drug candidates for treatment of Parkinson's disease. Folia Pharmacologica Japonica 131:4, pages 275-280.
Crossref
Crossref
Pier Giovanni Baraldi, Mojgan Aghazadeh Tabrizi, Stefania Gessi & Pier Andrea Borea. (2008) Adenosine Receptor Antagonists: Translating Medicinal Chemistry and Pharmacology into Clinical Utility. Chemical Reviews 108:1, pages 238-263.
Crossref
Crossref
Shigeo Okabe, Peggy Mason, Geert Keil, Maria Fitzgerald, Hugo Lagercrantz, Malin Rohdin, Norio Sakai, Makoto Sato, Shigeru Watanabe, Lloyd B. Minor, Walter Herzog, Gabriel Bertolesi, Sarah McFarlane, Douglas Steven Kerr, Hung-Hsiang Yu, Tzumin Lee, Tore A. Nielsen, Dick F. Swaab, Paul J. Lucassen, Tomomi Shindou, Jeffery R. Wickens, E. J. Lowe, Kati E. Draper, Qiong Wang, Brian O. Williams & Robert W. Grange. 2009. Encyclopedia of Neuroscience. Encyclopedia of Neuroscience
929
1027
.
Sergi Ferr?Francisco Ciruela, Amina S. Woods, Carme Lluis & Rafael Franco. (2007) Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends in Neurosciences 30:9, pages 440-446.
Crossref
Crossref
Sergi Ferr?Luigi F. Agnati, Francisco Ciruela, Carme Lluis, Amina S. Woods, Kjell Fuxe & Rafael Franco. (2007) Neurotransmitter receptor heteromers and their integrative role in ?local modules?: The striatal spine module. Brain Research Reviews 55:1, pages 55-67.
Crossref
Crossref
Marc Vendrell, Ester Angulo, Vicent Casadó, Carme Lluis, Rafael Franco, Fernando Albericio & Miriam Royo. (2007) Novel Ergopeptides as Dual Ligands for Adenosine and Dopamine Receptors. Journal of Medicinal Chemistry 50:13, pages 3062-3069.
Crossref
Crossref
J. D. Salamone, M. Correa, A. Farrar & S. M. Mingote. (2007) Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology 191:3, pages 461-482.
Crossref
Crossref
Andrew M. Farrar, Mariana Pereira, Francisco Velasco, Jörg Hockemeyer, Christa E. Müller & John D. Salamone. (2006) Adenosine A2A receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing. Psychopharmacology 191:3, pages 579-586.
Crossref
Crossref
Sarah Rose, Neil Ramsay Croft & Peter Jenner. (2007) The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Research 1133, pages 110-114.
Crossref
Crossref
Adriana Galvan & Thomas Wichmann. 2007. Gaba and the Basal Ganglia - From Molecules to Systems. Gaba and the Basal Ganglia - From Molecules to Systems
287
312
.
Stanley Fahn, Joseph Jankovic, Mark Hallett & Peter Jenner. 2007. Principles and Practice of Movement Disorders. Principles and Practice of Movement Disorders
205
231
.
Danqing Xiao, Elena Bastia, Yue-Hang Xu, Caroline L. Benn, Jang-Ho J. Cha, Tracy S. Peterson, Jiang-Fan Chen & Michael A. Schwarzschild. (2006)
Forebrain Adenosine A
2A
Receptors Contribute to l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Hemiparkinsonian Mice
. The Journal of Neuroscience 26:52, pages 13548-13555.
Crossref
Crossref
Ubaldo BonuccelliPaolo Del Dotto. (2006) New pharmacologic horizons in the treatment of Parkinson disease. Neurology 67:7_suppl_2.
Crossref
Crossref
Anthony H. V. Schapira, Erwan Bezard, Jonathan Brotchie, Frédéric Calon, Graham L. Collingridge, Borris Ferger, Bastian Hengerer, Etienne Hirsch, Peter Jenner, Nicolas Le Novère, José A. Obeso, Michael A. Schwarzschild, Umberto Spampinato & Giora Davidai. (2006) Novel pharmacological targets for the treatment of Parkinson's disease. Nature Reviews Drug Discovery 5:10, pages 845-854.
Crossref
Crossref
Sarah Rose, Michael J. Jackson, Lance A. Smith, Kim Stockwell, Louisa Johnson, Paolo Carminati & Peter Jenner. (2006) The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of l-DOPA in MPTP treated common marmosets. European Journal of Pharmacology 546:1-3, pages 82-87.
Crossref
Crossref
. (2006) Laser Literature Watch. Photomedicine and Laser Surgery 24:3, pages 424-453.
Crossref
Crossref